Abstract
The reported prevalence of PVT is in the range of 0.6-15.8% in patient with liver cirrhosis
or portal hypertension. If the patient has hepatocellular carcinoma, thrombus is likely to be
malignant thrombus. Malignancy, frequently of hepatic origin, is responsible for 21-24% of
over all cases. The overall mortality rate of chronic PVT has been reported to be less than
10%, but is increased to 26% when associated with hepatocellular carcinoma and cirrhosis.
However, no treatment guideline has been established on anticoagulant therapy for PVT in
patients with concomitant hepatocellular carcinoma and cirrhosis. Because actually it is not
easy to distinguish between malignant thrombus and benign thrombus in clinical aspect, PVT
in hepatocellular carcinoma are still debatable whether or not treatment when it diagnosed.
We present 3 cases of portal vein thrombosis successfully treated with anticoagulation in
hepatocellular carcinoma and liver cirrhosis, and we include a literature review.
Citations
Citations to this article as recorded by
- Evaluation of Low-Molecular-Weight Heparin for Treatment of Portal Vein Thrombosis in Liver Cirrhosis Patients
Ji Min Han, Youngil Koh, Sung Hwan Kim, Sung Yun Suh, Yoon Sook Cho, Jeong-Hoon Lee, Su Jong Yu, Jung-Hwan Yoon, Hye Sun Gwak
Medicina.2023; 59(2): 292. CrossRef